Annual check-up: which tests really matter?
The "check-up" industry has gained traction in Brazil in recent years. Packages with 30, 50 or even 100 tests are offered as synonymous with preventive care. The reality is more sober: many of these tests bring no benefit, expose patients to risks (incidental findings, unnecessary biopsies) and raise costs without changing outcomes.
Evidence-based medicine — particularly the recommendations of the Brazilian Ministry of Health/INCA and the USPSTF — guides a check-up by age group and risk factors, not by quantity.
The logic of screening
A good screening test must meet three conditions: the disease must have an asymptomatic period in which treating changes the outcome; the test must be reasonably accurate; and early treatment must bring real benefit, not merely move the diagnosis forward.
When these criteria are not met, the test can cause more harm than good.
What makes sense for most adults
- Blood pressure: measured at every appointment from age 18.
- Cholesterol and fasting glucose: from ages 35–40, especially with overweight or obesity, or earlier if there are other risk factors.
- Cervical cancer: ages 25 to 64, with an HPV-DNA test every 5 years (or a Pap smear every 3 years where the test is not yet available).
- Mammography: ages 50 to 74, every 2 years (40 to 49, after an individualized risk-benefit discussion).
- Colorectal cancer: ages 50 to 75 — in Brazil's public system (SUS), a fecal immunochemical test every 2 years; colonoscopy or other strategies, depending on the case.
- Up-to-date vaccination: influenza, pneumococcal, dT/dTpa, HPV, hepatitis B, herpes zoster. The adult vaccination record is frequently neglected.
- Mental health: screening for depression and anxiety — it is not a blood test, it is a good conversation.
Cervix
- Ages
- 25–64
- Method and interval
- HPV-DNA test every 5 years, if negative
- Note
- Where the test is unavailable: cytology every 3 years, after 2 normal results 1 year apart
Breast
- Ages
- 50–74
- Method and interval
- Mammography every 2 years
- Note
- 40–49 and 75 or older: on request, after a talk about risks and benefits. In the US (USPSTF 2024): 40–74
Colorectal
- Ages
- 50–75
- Method and interval
- Fecal immunochemical test every 2 years (SUS)
- Note
- In the US (USPSTF 2021): 45–75, by different methods
What usually is not worth it
- "Routine" MRI and CT scans without a clinical indication.
- Ultra-broad panels of tumor markers in people without symptoms.
- Routine electrocardiogram in an asymptomatic, low-risk young adult.
- "Hormonal check-ups" and serial lab measurements without a clinical hypothesis.
Each of these tests has an indication in specific situations — the problem is indiscriminate use.
A useful check-up is personalized
Age, family history, previous illnesses, habits and exposures determine which tests make sense for you. A sedentary 45-year-old man, whose father had a heart attack at 50, does not need the same panel as a 28-year-old female athlete. The appointment — with time, with listening, with a well-done physical exam — is what defines a good plan.
More testing does not mean more care. It often means more noise. A good Family Physician helps you choose what matters.
Frequently asked questions
Which tests should I have at my annual check-up?
There is no single list that fits everyone. The appropriate tests depend on age, sex, family history, previous illnesses and habits such as smoking. In general, they include blood pressure measurement, assessment of cardiovascular and metabolic risk and the cancer screenings recommended for your age group, plus a review of vaccinations. The appointment exists precisely to choose what makes sense for you.
Is a check-up with lots of tests worth it?
A 2019 Cochrane review, with 17 clinical trials and more than 250,000 participants, concluded that general health checks in adults without symptoms had little or no effect on total, cancer or cardiovascular mortality. Broad packages increase the chance of incidental findings and of unnecessary tests or procedures. Tests chosen according to age and risk tend to be more useful.
At what age should I start having mammograms?
In Brazil, the Ministry of Health recommends screening mammography every two years for women aged 50 to 74. Since 2025, women aged 40 to 49 without symptoms can also have the test through SUS, after a conversation about risks and benefits. In the United States, the USPSTF recommends a mammogram every two years from 40 to 74. Anyone with symptoms or high risk needs a specific assessment.
How often should I have a cervical screening (Pap) test?
Cervical cancer screening is indicated from age 25 to 64. In Brazil, the main test is now the HPV-DNA test, repeated every 5 years when negative. Where this test is not yet available, the Pap smear remains valid: after two normal results one year apart, it is done every 3 years. People who are immunosuppressed follow specific guidance.
References
- Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019;1(1):CD009009. doi.org/10.1002/14651858.CD009009.pub3
- Instituto Nacional de Câncer (INCA). Controle do câncer do colo do útero: detecção precoce [Internet]. Rio de Janeiro: INCA; 2022 [atualizado 2025 set 30; citado 2026 out 17]. www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-do-cancer-do-colo-do-utero/acoes/deteccao-precoce
- Brasil. Ministério da Saúde. Nota Técnica nº 626/2025-CGCAN/DECAN/SAES/MS: acesso das mulheres à mamografia no SUS. Brasília: Ministério da Saúde; 2025. www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/notas-tecnicas/2025/nota-tecnica-no-626-2025-cgcan-decan-saes-ms.pdf
- Instituto Nacional de Câncer (INCA). SUS inclui teste de alta tecnologia para rastreamento de câncer colorretal [Internet]. Rio de Janeiro: INCA; 2026 ago 10 [citado 2026 out 17]. www.gov.br/inca/pt-br/assuntos/noticias/2026/sus-inclui-teste-de-alta-tecnologia-para-rastreamento-de-cancer-colorretal
- US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, Coker TR, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918-30. doi.org/10.1001/jama.2024.5534
- US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-77. doi.org/10.1001/jama.2021.6238
